- ISIN
- US4169061052
- CUSIP
- 416906105
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- IPO Date
- Dec 7, 2000
Highlights
- Market Cap
- $27.51M
- Enterprise Value
- $26.77M
- EPS (TTM)
- -$2.20
- Total Revenue (TTM)
- $85.53M
- Gross Profit (TTM)
- $45.94M
- EBITDA (TTM)
- $53.53M
- Year Range
- $3.76 - $9.40
- Target Price
- $6.00
- ROA (TTM)
- -12.55%
- ROE (TTM)
- -97.39%
- Avg. Volume (1M)
- 12K
- Avg. Volume Value (1M)
- $73.38K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HBIO Performance Chart
Harvard Bioscience, Inc. (HBIO) is down 8.8% since the beginning of the year. At $6 per share, HBIO is trading 35.1% below its 52-week high of $9. Investors who bought $1,000 worth of HBIO shares 5 years ago would now be looking at an investment worth $77.
Loading charts...
Compare this symbol against anything
Returns By Period
Harvard Bioscience, Inc. (HBIO) has returned -8.79% so far this year and 39.88% over the past 12 months. Over the last ten years, HBIO has returned -14.23% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Harvard Bioscience, Inc.
- 1D
- 0.16%
- 1M
- -0.81%
- 6M
- 21.78%
- YTD
- -8.79%
- 1Y
- 39.88%
- 3Y*
- -48.71%
- 5Y*
- -40.07%
- 10Y*
- -14.23%
- ALL TIME*
- -8.23%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
HBIO Monthly Returns History
Based on dividend-adjusted daily data since Mar 19, 2001, HBIO's average daily return is +0.05%, while the average monthly return is +0.38%. At this rate, an investment would double in approximately 15.2 years.
Historically, 49% of months were positive and 51% were negative. The best month was Mar 2023 with a return of +48.4%, while the worst month was Feb 2025 at -50.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, HBIO closed higher 46% of trading days. The best single day was May 29, 2025 with a return of +135.7%, while the worst single day was Sep 18, 2002 at -52.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.10% | 22.52% | -20.65% | 31.01% | -7.84% | 4.59% | -0.81% | -8.79% | |||||
| 2025 | -18.96% | -50.67% | -32.90% | -37.05% | 31.07% | -4.97% | 4.93% | 6.29% | -11.41% | 17.81% | 47.31% | -12.12% | -68.30% |
| 2024 | -17.76% | -1.59% | -2.08% | -9.91% | -17.02% | -10.09% | 12.28% | -10.00% | -6.60% | -12.64% | -6.38% | -4.09% | -60.56% |
| 2023 | 7.58% | -5.03% | 48.41% | 36.19% | -2.27% | -1.79% | -15.30% | -5.16% | -2.49% | 2.09% | -2.96% | 25.59% | 93.14% |
| 2022 | -17.45% | -7.22% | 15.00% | -15.94% | -29.89% | -1.64% | 4.44% | -12.23% | -22.42% | 5.08% | -4.83% | 8.20% | -60.71% |
| 2021 | 8.16% | -5.39% | 24.37% | 26.92% | 1.01% | 19.00% | -5.28% | 4.69% | -15.50% | 7.88% | -11.16% | 5.38% | 64.34% |
Benchmark Metrics
Harvard Bioscience, Inc. has an annualized alpha of 4.37%, beta of 0.83, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since March 19, 2001.
- This stock participated in 153.08% of S&P 500 Index downside but only 86.50% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.37%
- Beta
- 0.83
- R²
- 0.06
- Upside Capture
- 86.50%
- Downside Capture
- 153.08%
Return for Risk
Risk / Return Rank
HBIO ranks 61 for risk / return — above 61% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Harvard Bioscience, Inc. (HBIO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HBIO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.07 | ||
| Sortino ratioReturn per unit of downside risk | -0.76 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.25 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.69 | 2.00 | -1.32 |
| Martin ratioReturn relative to average drawdown | 1.40 | 8.49 | -7.09 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Harvard Bioscience, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Harvard Bioscience, Inc. was 97.40%, occurring on May 28, 2025. The portfolio has not yet recovered.
The current Harvard Bioscience, Inc. drawdown is 94.41%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.40%May 2025 | 23y 9mo | — | 24y 11moSep 2001 - now | 2025 selloff2025 |
-27.93%Jun 2001 | 7d | 2mo 20d | 2mo 27dMay 2001 - Aug 2001 | Dot-com crash2000–2002 |
-17.19%Apr 2001 | 13d | 10d | 23dMar 2001 - Apr 2001 | Dot-com crash2000–2002 |
-6.74%Apr 2001 | 2d | 1d | 3dApr 2001 - Apr 2001 | Dot-com crash2000–2002 |
-5.21%May 2001 | 1d | 4d | 4dMay 2001 - May 2001 | Dot-com crash2000–2002 |
Drawdown Indicators
| HBIO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.40% | -56.78% | -40.62% |
Max Drawdown (1Y)Largest decline over 1 year | -45.24% | -9.10% | -36.14% |
Max Drawdown (3Y)Largest decline over 3 years | -94.82% | -18.90% | -75.92% |
Max Drawdown (5Y)Largest decline over 5 years | -96.64% | -25.43% | -71.21% |
Max Drawdown (10Y)Largest decline over 10 years | -96.64% | -33.92% | -62.72% |
Current DrawdownCurrent decline from peak | -94.41% | -1.58% | -92.83% |
Average DrawdownAverage peak-to-trough decline | -65.72% | -10.70% | -55.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.17% | 2.14% | +20.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Harvard Bioscience, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Harvard Bioscience, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HBIO relative to other companies in the Medical Instruments & Supplies industry. Currently, HBIO has a P/S ratio of 0.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HBIO in comparison with other companies in the Medical Instruments & Supplies industry. Currently, HBIO has a P/B value of 2.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HBIO
Add Harvard Bioscience, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HBIO